• 1
    Pasternak MS. Approach to the adult with recurrent infections. In: Basow DS, ed. Uptodate. Waltham, MA: UpToDate, 2013.
  • 2
    Sicherer SH, Winkelstein JA. Primary immunodeficiency diseases in adults. JAMA 1998; 279:5861.
  • 3
    Seymour B, Miles J, Haeney M. Primary antibody deficiency and diagnostic delay. J Clin Pathol 2005; 58:546547.
  • 4
    Blore J, Haeney MR. Primary antibody deficiency and diagnostic delay. BMJ 1989; 298:516517.
  • 5
    de Vries E. Clinical Working Party of the European Society for Immunodeficiencies (ESID). Patient-centred screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immunologists. Clin Exp Immunol 2006; 145:204214.
  • 6
    de Vries E. European Society for Immunodeficiencies (ESID) members. Patient-centred screening for primary immunodeficiency, a multi-stage diagnostic protocol designed for non-immunologists: 2011 update. Clin Exp Immunol 2012; 167:108119.
  • 7
    Minchinton RM, Dean MM, Clark TR, Heatley S, Mullighan CG. Analysis of the relationship between mannose-binding lectin (MBL) genotype, MBL levels and function in an Australian blood donor population. Scand J Immunol 2002; 56:630641.
  • 8
    Heitzeneder S, Seidel M, Forster-Waldl E, Heitger A. Mannan-binding lectin deficiency – good news, bad news, doesn't matter? Clin Immunol 2012; 143:2238.
  • 9
    Valles X, Roca A, Lozano F et al. Serotype-specific pneumococcal disease may be influenced by mannose-binding lectin deficiency. Eur Respir J 2010; 36:856863.
  • 10
    Vuononvirta J, Toivonen L, Grondahl-Yli-Hannuksela K et al. Nasopharyngeal bacterial colonization and gene polymorphisms of mannose-binding lectin and Toll-like receptors 2 and 4 in infants. PLOS ONE 2011; 6:e26198.
  • 11
    Eisen DP, Dean MM, Boermeester MA et al. Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection. Clin Infect Dis 2008; 47:510516.
  • 12
    Brouwer MC, Baas F, van der Ende A, van de Beek D. Genetic variation and cerebrospinal fluid levels of mannose binding lectin in pneumococcal meningitis patients. PLOS ONE 2013; 8:e65151.
  • 13
    Endeman H, Herpers BL, de Jong BA et al. Mannose-binding lectin genotypes in susceptibility to community-acquired pneumonia. Chest 2008; 134:11351140.
  • 14
    Garcia-Laorden MI, Sole-Violan J, Rodriguez de Castro F et al. Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults. J Allergy Clin Immunol 2008; 122:368374. 374.e1–2.
  • 15
    Neth O, Jack DL, Dodds AW, Holzel H, Klein NJ, Turner MW. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000; 68:688693.
  • 16
    Krarup A, Sorensen UB, Matsushita M, Jensenius JC, Thiel S. Effect of capsulation of opportunistic pathogenic bacteria on binding of the pattern recognition molecules mannan-binding lectin, L-ficolin, and H-ficolin. Infect Immun 2005; 73:10521060.
  • 17
    Brouwer N, Dolman KM, van Houdt M, Sta M, Roos D, Kuijpers TW. Mannose-binding lectin (MBL) facilitates opsonophagocytosis of yeasts but not of bacteria despite MBL binding. J Immunol 2008; 180:41244132.
  • 18
    Gadjeva M, Takahashi K, Thiel S. Mannan-binding lectin – a soluble pattern recognition molecule. Mol Immunol 2004; 41:113121.
  • 19
    Worthley DL, Bardy PG, Mullighan CG. Mannose-binding lectin: biology and clinical implications. Intern Med J 2005; 35:548555.
  • 20
    Bronkhorst MW, Bouwman LH. Mannose-binding lectin deficiency. In: Basow DS, ed. Uptodate. Waltham, MA: UpToDate, 2013.
  • 21
    Celli BR, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932946.
  • 22
    Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party for Standardization of Lung Function Tests, European Community for Steel and Coal, Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16:540.
  • 23
    Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532555.
  • 24
    Settipane GA, Pudupakkam RK, McGowan JH. Corticosteroid effect on immunoglobulins. J Allergy Clin Immunol 1978; 62:162166.
  • 25
    Posey WC, Nelson HS, Branch B, Pearlman DS. The effects of acute corticosteroid therapy for asthma on serum immunoglobulin levels. J Allergy Clin Immunol 1978; 62:340348.
  • 26
    Seelen MA, Roos A, Wieslander J et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods 2005; 296:187198.
  • 27
    Pickering JW, Martins TB, Greer RW et al. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. Am J Clin Pathol 2002; 117:589596.
  • 28
    Bonilla FA, Bernstein IL, Khan DA et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005; 5 (Suppl 1):S163.
  • 29
    Geha RS, Notarangelo LD, Casanova JL et al. Primary immunodeficiency diseases: an update from the international union of immunological societies primary immunodeficiency diseases classification committee. J Allergy Clin Immunol 2007; 120:776794.
  • 30
    Vlug A, Nieuwenhuys EJ, van Eijk RV, Geertzen HG, van Houte AJ. Nephelometric measurements of human IgG subclasses and their reference ranges. Ann Biol Clin (Paris) 1994; 52:561567.
  • 31
    Whaley MJ, Rose C, Martinez J et al. Interlaboratory comparison of three multiplexed bead-based immunoassays for measuring serum antibodies to pneumococcal polysaccharides. Clin Vaccine Immunol 2010; 17:862869.
  • 32
    van Kessel DA, van Velzen-Blad H, van den Bosch JM, Rijkers GT. Impaired pneumococcal antibody response in bronchiectasis of unknown aetiology. Eur Respir J 2005; 25:482489.
  • 33
    Jackson LA, Gurtman A, van Cleeff M et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31:35773584.
  • 34
    Chen M, Hisatomi Y, Furumoto A et al. Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination. Clin Vaccine Immunol 2007; 14:139145.
  • 35
    Butler WT, Rossen RD. Effects of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone. J Clin Invest 1973; 52:26292640.
  • 36
    de Roux A, Schmidt N, Rose M, Zielen S, Pletz M, Lode H. Immunogenity of the pneumococcal polysaccharide vaccine in COPD patients. The effect of systemic steroids. Respir Med 2004; 98:11871194.
  • 37
    Steentoft J, Konradsen HB, Hilskov J, Gislason G, Andersen JR. Response to pneumococcal vaccine in chronic obstructive lung disease – the effect of ongoing, systemic steroid treatment. Vaccine 2006; 24:14081412.
  • 38
    Casanova JL, Abel L. Human mannose-binding lectin in immunity: friend, foe, or both? J Exp Med 2004; 199:12951299.